Rosette-Forming Glioneuronal Tumor of the Fourth Ventricle: A Case of Relapse Treated with Proton Beam Therapy.
Antonella CacchioneAngela MastronuzziAndrea CaraiGiovanna Stefania ColafatiFrancesca Diomedi-CamasseiAntonio MarrazzoAlessia CarboniEvelina MieleLucia PedaceMarco TartagliaMaurizio AmichettiFrancesco FellinMariachiara LodiSabina VennariniPublished in: Diagnostics (Basel, Switzerland) (2021)
Rosette-forming glioneuronal tumors (RGNTs) are rare, grade I, central nervous system (CNS) tumors typically localized to the fourth ventricle. We describe a 9-year-old girl with dizziness and occipital headache. A magnetic resonance imaging (MRI) revealed a large hypodense posterior fossa mass lesion in relation to the vermis, with cystic component. Surgical resection of the tumor was performed. A RGNT diagnosis was made at the histopathological examination. During follow-up, the patient experienced a first relapse, which was again surgically removed. Eight months after, MRI documented a second recurrence at the local level. She was a candidate for the proton beam therapy (PBT) program. Three years after the end of PBT, the patient had no evidence of disease recurrence. This report underlines that, although RGNTs are commonly associated with an indolent course, they may have the potential for aggressive behavior, suggesting the need for treatment in addition to surgery. Controversy exists in the literature regarding effective management of RGNTs. Chemotherapy and radiation are used as adjuvant therapy, but their efficacy management has not been adequately described in the literature. This is the first case report published in which PBT was proposed for adjuvant therapy in place of chemotherapy in RGNT relapse.
Keyphrases
- case report
- free survival
- magnetic resonance imaging
- contrast enhanced
- systematic review
- diffusion weighted imaging
- pulmonary artery
- computed tomography
- pulmonary hypertension
- locally advanced
- minimally invasive
- mitral valve
- magnetic resonance
- coronary artery bypass
- randomized controlled trial
- squamous cell carcinoma
- congenital heart disease
- cerebrospinal fluid
- quality improvement
- combination therapy
- bone marrow
- risk assessment
- chemotherapy induced
- stem cells
- climate change
- electron transfer
- pulmonary arterial hypertension
- replacement therapy